GlassScriptPhysician profile
Meghan Kunz
NPI 1508129834
$1,615.66
in general payments reported to CMS, 2019-2025
18 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $527 · 2022: $468 · 2023: $343 · 2024: $133 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $620.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $662.04 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $204.74 | 2021-2024 | Invega Sustenna, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $108.04 | 2021-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $95.29 | 2021-2025 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $93.88 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.54 | 2022-2025 | Caplyta |
| Alkermes, INC. | $78.24 | 2021-2023 | Lybalvi |
| Lundbeck LLC | $54.41 | 2021-2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $46.59 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $35.51 | 2021-2023 | Rexulti |
| Collegium Pharmaceutical, INC. | $26.24 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $26.00 | 2021 | |
| Neurocrine Biosciences, INC. | $24.01 | 2021 | |
| Corium, LLC | $17.37 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $15.70 | 2023 | Auvelity |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $14.47 | 2024 | Zurzuvae |
| Adlon Therapeutics L.P. | $14.16 | 2021 | |
| Alfasigma USA, INC. | $13.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Kunz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.